LIDDS

0,02 SEK

-33,14 %

Mindre end 1K følgere

LIDDS

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

-33,14 %

-47,73 %

-52,67 %

-62,05 %

-74,44 %

-83,51 %

-98,50 %

-99,83 %

-99,76 %

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

Markedsværdi

3,14 mio. SEK

Aktieomsætning

34,07 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

19.2

2026

Årsrapport '25

28.5

2026

Delårsrapport Q1'26

28.5

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelsefor 13 timer siden

Notice of extraordinary general meeting, as well as the second control meeting, in LIDDS AB (publ)

Selskabsmeddelelsefor 14 timer siden

LIDDS AB (publ) proposes that the general meeting, as well as the second control meeting, resolve on voluntary liquidation and the delisting of the company’s shares

Selskabsmeddelelse18.12.2025, 10.30

Announcement from extraordinary general meeting in LIDDS AB (publ) held on 18 December 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse10.12.2025, 18.00

LIDDS AB (publ) has decided to terminate the process regarding the reverse acquisition of Proport Invest AB (publ).

Selskabsmeddelelse1.12.2025, 16.15

Change of Certified Adviser (CA) to G&W Fondkommission

Selskabsmeddelelse27.11.2025, 17.30

LIDDS AB (publ) has entered into an agreement for a reverse takeover of Proport Invest AB (publ)

Selskabsmeddelelse20.11.2025, 06.00

LIDDS AB (publ) Interim Report January – September 2025

Selskabsmeddelelse13.11.2025, 20.20

Notice of extraordinary general meeting in LIDDS AB (publ)

Pressemeddelelse13.11.2025, 20.10

The board of directors of LIDDS AB intends to propose a reduction of the company’s share capital for loss coverage

Selskabsmeddelelse28.8.2025, 06.00

LIDDS AB (publ) Interim Report January – June 2025

Selskabsmeddelelse28.5.2025, 09.00

Announcement from Annual General Meeting, also first control meeting, in LIDDS AB (publ), held on 28 May 2025

Selskabsmeddelelse28.5.2025, 06.32

Correction: LIDDS AB (publ) Interim Report January – March 2025

Selskabsmeddelelse28.5.2025, 06.00

LIDDS AB (publ) Interim Report January – March 2024

Selskabsmeddelelse6.5.2025, 06.00

LIDDS’ Annual Report 2024 published

Selskabsmeddelelse25.4.2025, 08.15

Notice to the Annual General Meeting, and first Control Meeting, of LIDDS AB (publ)

Selskabsmeddelelse24.4.2025, 20.45

Balance Sheet shows that the Equity in LIDDS AB is Less than Half of the Registered Share Capital and the Board will therefore convene a First Control Meeting

Selskabsmeddelelse22.4.2025, 06.10

The Board of Directors resolves to prepare a balance sheet for liquidation purposes

Selskabsmeddelelse10.4.2025, 11.30

LIDDS has decided to write-down intangible assets

Selskabsmeddelelse2.4.2025, 13.00

LIDDS has decided to cease further development

Selskabsmeddelelse20.2.2025, 07.00

LIDDS AB (publ) Year-end Report 2024

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.